Sangamo Biosciences Inc. has announced that early data from an ALS clinical trial showed improvement in muscle function in ALS patients. Sangamo reported that 32 percent of patients who received SB-509 had improved muscle function, compared to 17 percent of untreated patients. Muscle function was evaluated by manual testing of 34 muscles. SB-509 is an injectable formulation of a plasmid encoding a zinc finger DNA-binding protein transcription factor (ZFP TF(TM)) designed to upregulate the expression of the gene encoding vascular endothelial growth factor (VEGF-A).
Click here to read more.Share this: